A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations

被引：3
作者：
Lu, S. [1 ]
Zhou, J. [2 ]
Niu, X. [3 ]
Chen, M. [4 ]
Hua, Y. [4 ]
Su, W. [4 ]
机构：
[1] Shanghai Chest Hosp, Oncol, Shanghai, Peoples R China
[2] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Resp Dis, Hangzhou, Zhejiang, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Shanghai Lung Canc Ctr, Shanghai, Peoples R China
[4] Hutchison Medipharma, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Fruquintinib; non-small cell lung cancer; gefitinib;
D O I：
10.1016/j.jtho.2017.09.1511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-070
引用
收藏
页码：S2228 / S2228
页数：1
相关论文
共 50 条
  • [31] Preliminary Efficacy and Safety Results About a Phase II Trial of Afatinib and Bevacizumab in Untreated NSCLC Harboring EGFR Sensitive Mutations
    Feng, Y.
    Zhuo, M.
    Zhao, J.
    Zhang, H.
    Qin, H.
    Shi, Q.
    Huang, Y.
    Liu, Y.
    Hu, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1103 - S1104
  • [32] Rationale and Design of a Phase II Trial of Dacomitinib in Advanced NSCLC Patients with Uncommon EGFR Mutations
    Han, B.
    Zhang, B.
    Shi, C.
    Gao, Z.
    Zhong, H.
    Xiong, L.
    Gu, A.
    Wang, W.
    Chu, T.
    Zhang, W.
    Wang, H.
    Zhang, X.
    Zhong, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S613 - S613
  • [33] A Multicenter, Non-Interventional Study on Real World EGFR Testing and in Patients with IIIB/IV NSCLC in Northern China
    Cheng, Y.
    Wang, Y.
    Zhao, J.
    Liu, Y.
    Gao, H.
    Ma, K.
    Zhang, S.
    Xin, H.
    Liu, J.
    Chengbo, H.
    Zhu, Z.
    Wang, Y.
    Chen, J.
    Wen, F.
    Li, J.
    Jie, Z.
    Zheng, Z.
    Dai, Z.
    Piao, H.
    Li, X.
    Li, Y.
    Zhong, M.
    Ma, R.
    Zhuang, Y.
    Xu, Y.
    Qu, Z.
    Yang, H.
    Pan, C.
    Yang, F.
    Zhang, D.
    Li, B.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1734 - S1735
  • [34] Classification of EGFR Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV NSCLC
    Yang, Lin
    Tang, Chuanhao
    Xu, Bin
    Wang, Weixia
    Li, Jianjie
    Li, Xiaoyan
    Qin, Haifeng
    Gao, Hongjun
    He, Kun
    Song, Santai
    Liu, Xiaoqing
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S299 - S300
  • [35] Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations
    Masuda, T.
    Imai, H.
    Kuwako, T.
    Miura, Y.
    Yoshino, R.
    Kaira, K.
    Shimizu, K.
    Sunaga, N.
    Tomizawa, Y.
    Ishihara, S.
    Mogi, A.
    Hisada, T.
    Minato, K.
    Takise, A.
    Saito, R.
    Yamada, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (09) : 702 - 709
  • [36] Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations
    T. Masuda
    H. Imai
    T. Kuwako
    Y. Miura
    R. Yoshino
    K. Kaira
    K. Shimizu
    N. Sunaga
    Y. Tomizawa
    S. Ishihara
    A. Mogi
    T. Hisada
    K. Minato
    A. Takise
    R. Saito
    M. Yamada
    Clinical and Translational Oncology, 2015, 17 : 702 - 709
  • [37] Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis
    Daichi Fujimoto
    Hiroyuki Ueda
    Ryoko Shimizu
    Ryoji Kato
    Takehiro Otoshi
    Takahisa Kawamura
    Koji Tamai
    Yumi Shibata
    Takeshi Matsumoto
    Kazuma Nagata
    Kyoko Otsuka
    Atsushi Nakagawa
    Kojiro Otsuka
    Nobuyuki Katakami
    Keisuke Tomii
    Clinical & Experimental Metastasis, 2014, 31 : 543 - 551
  • [38] Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)
    Popat, Sanjay
    Hsia, Te-Chun
    Hung, Jen-Yu
    Jung, Hyun Ae
    Shih, Jin-Yuan
    Park, Cheol Kyu
    Lee, Seung Hyeun
    Okamoto, Tatsuro
    Ahn, Hee Kyung
    Lee, Yong Chul
    Sato, Yuki
    Lee, Sung Sook
    Mascaux, Celine
    Daoud, Hasan
    Marten, Angela
    Miura, Satoru
    ONCOLOGIST, 2022, 27 (04) : 255 - 265
  • [39] A Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001
    Ichihara, Eiki
    Hotta, Katsuyuki
    Nogami, Naoyuki
    Kuyama, Shoichi
    Kishino, Daizo
    Fujii, Masanori
    Kozuki, Toshiyuki
    Tabata, Masahiro
    Harada, Daijiro
    Chikamori, Kenichi
    Aoe, Keisuke
    Ueoka, Hiroshi
    Hosokawa, Shinobu
    Bessho, Akihiro
    Hisamoto-Sato, Akiko
    Kubo, Toshio
    Oze, Isao
    Takigawa, Nagio
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (03) : 486 - 491
  • [40] A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01)
    Asami, Kazuhiro
    Ando, Masahiko
    Nishimura, Takashi
    Yokoi, Takashi
    Tamura, Atsuhisa
    Minato, Koichi
    Mori, Masahide
    Ogushi, Fumitaka
    Yamamoto, Akiyoshi
    Yoshioka, Hiroshige
    Kawahara, Masaaki
    Atagi, Shinji
    THORACIC CANCER, 2022, 13 (12) : 1827 - 1836
12345